Depression, Antidepressants, Epigenetic Aging, and Mortality in Postmenopausal Women | Aging-US

Aging-US #published this #trending research paper on May 27, 2024 in Volume 16, Issue 10, entitled, "Relationships of depression and antidepressant use with epigenetic age acceleration and all-cause mortality among postmenopausal women" by researchers from the Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIA/NIH/IRP, Baltimore, MD; VA National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, Washington, DC; Department of Management, Policy, and Community Health, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Department of Biostatistics, School of Public Health, University of California Los Angeles, Los Angeles, CA; Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Herbert Wertheim School of Public Health and Human Longevity Science and Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, University of California, San Diego, CA; Department of Epidemiology, Fielding School of Public Health, Translational Sciences Section, School of Nursing, University of California, Los Angeles, CA; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY; Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC; Department of Family and Community Medicine (Emeritus), School of Medicine, University of Nevada, Reno, NV. ‪@NIHAging‬
#aging #research #depression #antidepressant #postmenopause #women #researchpaper #openaccess #openscience #peerreview #journal #publication #publishing #meded
DOI - doi.org/10.18632/aging.205868
Corresponding author - May A. Beydoun - [e-mail]
Abstract
We investigated relations of depressive symptoms, antidepressant use, and epigenetic age acceleration with all-cause mortality risk among postmenopausal women. Data were analyzed from approximately 1,900 participants in the Women's Health Initiative study testing four-way decomposition models. After a median 20.4y follow-up, 1,161 deaths occurred. Approximately 11% had elevated depressive symptoms (EDS+), 7% were taking antidepressant medication at baseline (ANTIDEP+), while 16.5% fell into either category (EDS_ANTIDEP+). Baseline ANTIDEP+, longitudinal transition into ANTIDEP+ and accelerated epigenetic aging directly predicted increased mortality risk. GrimAge DNA methylation age acceleration (AgeAccelGrim) partially mediated total effects of baseline ANTIDEP+ and EDS_ANTIDEP+ on all-cause mortality risk in socio-demographic factors-adjusted models (Pure Indirect Effect greter than 0, P less than 0.05; Total Effect gretaer than 0, P less than 0.05). Thus, higher AgeAccelGrim partially explained the relationship between antidepressant use and increased all-cause mortality risk, though only prior to controlling for lifestyle and health-related factors. Antidepressant use and epigenetic age acceleration independently predicted increased all-cause mortality risk. Further studies are needed in varying populations.
Sign up for free Altmetric alerts about this article -
aging.altmetric.com/details/e...
Subscribe for free publication alerts from Aging - www.aging-us.com/subscribe-to...
Keywords - aging, depressive symptoms, epigenetic age acceleration, mortality
About Aging-US
Aging publishes research papers in all fields of aging research, including but not limited to aging processes (from yeast to mammals), cellular senescence, age-related diseases (such as cancer and Alzheimer’s disease) and their prevention and treatment, anti-aging strategies and drug development, and, importantly, the role of signal transduction pathways in aging (such as mTOR) and potential approaches to modulate these signaling pathways to extend lifespan.
The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)
Please visit our website at www.Aging-US.com​​ and connect with us:
Facebook - / agingus
X - / agingjrnl
Instagram - / agingjrnl
CZcams - / @agingjournal
LinkedIn - / aging
Pinterest - / agingus
Spotify - open.spotify.com/show/1X4HQQg...
Media Contact
18009220957
[e-mail]